Please note, Alexar has changed its name to Ralexar
The company is developing topical and systemic therapies based on Liver X Receptor (LXR) modulators. The initial focus for the company is on the clinical development of ALX-101, a topical LXR-based therapy, for the treatment of various cutaneous inflammatory disorders, including atopic dermatitis.
May 31, 2017
Mar 30, 2016